



GENZYME EUROPE BV
GOOIMEER 10
1411 DD NAARDEN
NETHERLANDS
Tel: +31-35-699-1200
Fax: +31-35-694-3214

17-02-2010

***Healthcare Professional Communication – further delay in the supply of Cerezyme®
(imiglucerase)***

Dear Healthcare Professional,

In December 2009, Genzyme informed the Gaucher community that we were on track to begin shipping newly manufactured Cerezyme at the end of 2009, and anticipated that previously treated patients will be able to resume normal dosing of Cerezyme within the first three months of 2010. Genzyme would like to provide an update on the status of Cerezyme supply:

- Genzyme began to distribute Cerezyme as soon as newly manufactured drug became available, given the period following the shortage in 2009, and nearly 80 percent of patients resumed normal dosing in the first weeks of 2010. Cerezyme production is continuing successfully, however, as a result of not having adequate inventory, shipping delays affected treatment logistics for many patients in February. In order to avoid additional shipping interruptions during this time of high demand and low inventory, **Genzyme will ship 50 percent of demand for an eight-week period from February 22 – through April 16, 2010.** By taking this step now, Genzyme can build a level of inventory which will allow a more predictable schedule of Cerezyme delivery in the coming months and allow patients to return to normal dosing after 16 April of 2010.
- **Due to this problem, during the current shortage, the treatment recommendations as communicated in the previous DHPC (October 2009) will be reinstated.**
- **All patients, especially those receiving Cerezyme at a lower dose or at a reduced frequency should be closely monitored** for changes in haemoglobin, platelets and chitotriosidase levels, as appropriate, at baseline and bimonthly thereafter. Adults who demonstrate exacerbation of disease while on dose reduction/dose interruption are at high risk for the development of progressive disease or complications and should reinstate the original treatment with Cerezyme, or alternative treatment should be considered.

Adverse events for Cerezyme should continue to be reported as usual and physicians are reminded to document batch numbers in the patient record.

These are temporary recommendations and do not change the currently approved Product Information for Cerezyme. **The recommendations only apply until the 16th April.**



Should you require any further information, please contact Genzyme local entity via e-mail UKmedinfo@genzyme.com or telephone +44 (0) 1865 405283

Yours sincerely,

A handwritten signature in black ink, appearing to read "Carlo Incerti". The signature is fluid and cursive, with a long horizontal stroke extending to the right.

Carlo Incerti, MD.
Head of R&D Europe